Avecho Biotechnology Ltd - A positive Phase III interim analysis

101 Views25 Jun 2026 09:00

Issuer-paid

SUMMARY

Avecho Biotechnology Limited (ASX:AVE) is an Australian biotech company currently focused on a CBD (Cannabidiol) soft-gel capsule for insomnia.
It is presently undergoing a pivotal Phase III clinical trial with the potential to be the first over-the-counter (OTC) CBD drug approved by Australia’s Therapeutic Goods Administration (TGA).
On 24 June 2026, AVE announced its much-anticipated interim Phase III trial results, which is consistent with a treatment effect sufficient to continue at the originally planned sample size; this is the first insight on efficacy since the trial started in March 2024.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream